Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05358951
Other study ID # 21-613
Secondary ID R21CA261863
Status Recruiting
Phase N/A
First received
Last updated
Start date November 19, 2022
Est. completion date April 30, 2025

Study information

Verified date March 2024
Source Dana-Farber Cancer Institute
Contact STEP-YA Study Coordinator
Phone 617-582-8260
Email step@dfci.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to learn if a single online education session, with or without individualized coaching sessions, can help improve young adult cancer survivors' (YACS) sleep. The name of the study intervention is Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA).


Description:

This study is a randomized controlled trial of young adult cancer survivors with clinically significant symptoms of insomnia to evaluate the cognitive-behavioral based Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA). All participants will take part in a single STEP-YA session, during which they will complete baseline measures prior to randomization and then receive the STEP-YA intervention. Participants will then be randomly assigned to receive the STEP-YA intervention either, 1) alone (non-coaching condition), or 2) with the addition of 2 remote coaching sessions (coaching condition). Participants will also complete follow-up measures 4 and 8 weeks post-baseline. It expected that about 74 people will take part in this study


Recruitment information / eligibility

Status Recruiting
Enrollment 74
Est. completion date April 30, 2025
Est. primary completion date April 30, 2025
Accepts healthy volunteers No
Gender All
Age group 20 Years to 39 Years
Eligibility Inclusion Criteria: To be determined by patient self-report from eligibility screening with potential participants. (See Appendix A for eligibility screening materials). Participants must be screened for eligibility =2 weeks prior to study enrollment. Participants who are screened earlier must be rescreened within this period. - Age 20-39 - History of a cancer diagnosis (except non-melanoma skin cancer) = 1 year prior - No active cancer therapy (excluding chemoprevention) in the past four months, and no further therapy planned - Significant insomnia as evidenced by an Insomnia Severity Index score =12 - Able to read and write in English Exclusion Criteria: - Survivors who report ever being diagnosed with Bipolar Disorder. - Survivors who report ever being diagnosed with a Seizure Disorder or have experienced a seizure in the past 12 months. - Intention to adjust (decrease or increase) use of any prescribed or over-the-counter medications taken to decrease insomnia during the study period. - Survivors who report being diagnosed with sleep apnea who are not receiving recommended medical treatment for their sleep apnea (as assessed by screening questions, see Appendix A). - Survivors who report suspected sleep apnea who have not completed an evaluation by a sleep specialist (as assessed by screening questions, see Appendix A). - Survivors who report their usual bedtime does not fall between 5:00 pm and 5:00 am. - Employment that involves irregular sleep patterns, such as shift-work or frequent long-distance travel across time zones, or employment in a position that could impact public safety (such as air traffic-controller, operating heavy machinery) - Any impairment (e.g., hearing, visual, cognitive) that interferes with the ability to complete all study procedures independently. - Prior participation in a research study which provided an educational or behavioral intervention for insomnia - Prior participation in a behavioral treatment or patient education program for insomnia delivered at the Dana-Farber Cancer Institute, or at Boston Children's Hospital. - Participation in behavioral or educational interventions for insomnia in the 2 years prior to enrollment. This includes in-person as well as synchronous and asynchronous online insomnia programs, but not independent use of books, workbooks or other written self-help materials addressing insomnia.

Study Design


Related Conditions & MeSH terms

  • Cancer
  • Insomnia
  • Insomnia Due to Medical Condition
  • Sleep Initiation and Maintenance Disorders

Intervention

Behavioral:
STEP-YA with Coaching
Online instruction on behavioral changes to improve sleep with 2 additional individually coached session
STEP-YA without Coaching
Online instruction on behavioral changes to improve sleep without additional individually coached session

Locations

Country Name City State
United States Dana-Farber Cancer Institute Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Insomnia Severity at 16 weeks (optional) The Insomnia Severity Index (ISI), a 7-item self-report questionnaire assessing severity, and impact of insomnia symptoms will be used. 16 weeks post-intervention session
Other Initial Satisfaction with Intervention Session Study specific questionnaire assessing intervention acceptability, credibility and participant satisfaction Up to 4 weeks post-intervention
Other Satisfaction with Coaching Sessions Study specific questionnaire describing satisfaction with coaching sessions Up to 4 weeks post-intervention
Other Final satisfaction with the intervention Study specific questionnaire asking about participant satisfaction with the intervention 8 Weeks post-intervention session
Primary Insomnia Severity Change at 8 Weeks The Insomnia Severity Index (ISI), a 7-item self-report questionnaire assessing severity, and impact of insomnia symptoms will be used. Baseline to 8-weeks post-intervention session
Secondary Profile of Mood States Change at 8 weeks The Profile of Mood States - Short Form (POMS-SF), a 35-item measure of participant mood states that provides multiple scales including an overall Total Mood Disturbance (TMD) score will be used Baseline to 8-weeks post-intervention session
Secondary Profile of Mood States Change at 4 weeks The Profile of Mood States - Short Form (POMS-SF), a 35-item measure of participant mood states that provides multiple scales including an overall Total Mood Disturbance (TMD) score will be used Baseline to 4-weeks post-intervention session
Secondary Insomnia Severity Change at 4 weeks The Insomnia Severity Index (ISI), a 7-item self-report questionnaire assessing severity, and impact of insomnia symptoms will be used. Baseline to 4-weeks post-intervention session
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients